To examine the role of nuclear factor (NF)-κB in T cell development and activation in vivo, we produced transgenic mice that express a superinhibitory mutant form of inhibitor κB-α (IκB-αA32/36) under the control of the T cell–specific CD2 promoter and enhancer (mutant [m]IκB-α mice). Thymocyte development proceeded normally in the mIκB-α mice. However, the numbers of peripheral CD8+ T cells were significantly reduced in these animals. The mIκB-α thymocytes displayed a marked proliferative defect and significant reductions in interleukin (IL)-2, IL-3, and granulocyte/macrophage colony-stimulating factor production after cross-linking of the T cell antigen receptor. Perhaps more unexpectedly, double positive (CD4+CD8+; DP) thymocytes from the mIκB-α mice were resistant to α-CD3–mediated apoptosis in vivo. In contrast, they remained sensitive to apoptosis induced by γ-irradiation. Apoptosis of wild-type DP thymocytes after in vivo administration of α-CD3 mAb was preceded by a significant reduction in the level of expression of the antiapoptotic gene, bcl-xL. In contrast, the DP mIκB-α thymocytes maintained high level expression of bcl-xL after α-CD3 treatment. Taken together, these results demonstrated important roles for NF-κB in both inducible cytokine expression and T cell proliferation after TCR engagement. In addition, NF-κB is required for the α-CD3–mediated apoptosis of DP thymocytes through a pathway that involves the regulation of the antiapoptotic gene, bcl-xL.
Skip Nav Destination
Article navigation
4 January 1999
Article|
January 04 1999
An Essential Role for Nuclear Factor κB in Promoting Double Positive Thymocyte Apoptosis
Thore Hettmann,
Thore Hettmann
From the *Departments of Medicine and Pathology, University of Chicago, Chicago, Illinois 60637; and the ‡Department of Pharmacology, University of California San Diego, San Diego, California 92093
Search for other works by this author on:
Joseph DiDonato,
Joseph DiDonato
From the *Departments of Medicine and Pathology, University of Chicago, Chicago, Illinois 60637; and the ‡Department of Pharmacology, University of California San Diego, San Diego, California 92093
Search for other works by this author on:
Michael Karin,
Michael Karin
From the *Departments of Medicine and Pathology, University of Chicago, Chicago, Illinois 60637; and the ‡Department of Pharmacology, University of California San Diego, San Diego, California 92093
Search for other works by this author on:
Jeffrey M. Leiden
Jeffrey M. Leiden
From the *Departments of Medicine and Pathology, University of Chicago, Chicago, Illinois 60637; and the ‡Department of Pharmacology, University of California San Diego, San Diego, California 92093
Search for other works by this author on:
Thore Hettmann
From the *Departments of Medicine and Pathology, University of Chicago, Chicago, Illinois 60637; and the ‡Department of Pharmacology, University of California San Diego, San Diego, California 92093
Joseph DiDonato
From the *Departments of Medicine and Pathology, University of Chicago, Chicago, Illinois 60637; and the ‡Department of Pharmacology, University of California San Diego, San Diego, California 92093
Michael Karin
From the *Departments of Medicine and Pathology, University of Chicago, Chicago, Illinois 60637; and the ‡Department of Pharmacology, University of California San Diego, San Diego, California 92093
Jeffrey M. Leiden
From the *Departments of Medicine and Pathology, University of Chicago, Chicago, Illinois 60637; and the ‡Department of Pharmacology, University of California San Diego, San Diego, California 92093
Address correspondence to Jeffrey M. Leiden, University of Chicago, Rm. B608 MC 6080, 5841 South Maryland Ave., Chicago, IL 60637. Phone: 773-702-1919; Fax: 773-702-1385; E-mail: [email protected]
Thore Hettmann is a Terry Fox Research Fellow. This work was supported in part by a grant from the NIAID to J.M. Leiden (2 R37 A129637-07) and by the Cancer Center of the University of Chicago, and by a grant from the NIAID to M. Karin (R01 AI43477-01).
Received:
July 06 1998
Revision Received:
October 05 1998
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1999
J Exp Med (1999) 189 (1): 145–158.
Article history
Received:
July 06 1998
Revision Received:
October 05 1998
Citation
Thore Hettmann, Joseph DiDonato, Michael Karin, Jeffrey M. Leiden; An Essential Role for Nuclear Factor κB in Promoting Double Positive Thymocyte Apoptosis . J Exp Med 4 January 1999; 189 (1): 145–158. doi: https://doi.org/10.1084/jem.189.1.145
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement